Understand the source comparison
Do Peptides Help With Healing — Comparison
BPC-157 VEGFR2 activation, angiogenesis Proliferation (days 4–21) Strong (multiple RCTs, 40–60% faster closure) Topical, subcutaneous, oral First-choice for acute traumatic wounds and vascular injury. Broad tissue affinity Thymosin Beta-4 Actin regulation, cel
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157
- VEGFR2 activation, angiogenesis
- Proliferation (days 4–21)
- Strong (multiple RCTs, 40–60% faster closure)
- Topical, subcutaneous, oral
- First-choice for acute traumatic wounds and vascular injury. Broad tissue affinity
- Thymosin Beta-4
- Actin regulation, cell migration
- Inflammation to proliferation transition (days 3–7)
- Strong (FDA Phase 3 trials ongoing for diabetic ulcers)
- Topical, subcutaneous
- Optimal for chronic wounds stuck in inflammatory phase. Requires consistent dosing
- GHK-Cu
- TGF-β activation, MMP-2 upregulation
- Remodeling (weeks 3–12)
- Moderate (smaller trials, 50–70% collagen increase in vitro)
- Topical, intradermal
- Best for scar reduction and collagen quality. Less effective for acute closure speed
- LL-37 (Antimicrobial Peptide)
- Immune modulation, bacterial membrane disruption
- Inflammation control (days 1–5)
- Moderate (preclinical + small human trials)
- Topical
- Use when infection risk is high. Pairs well with angiogenic peptides for dual action
- Collagen Peptides (Hydrolysed)
- Substrate provision for collagen synthesis
- Remodeling (weeks 2–8)
- Weak (mostly observational, high placebo effect)
- Oral
- Marginal clinical benefit unless baseline protein intake is deficient. Structural support only